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a b s t r a c t
Retinoic acid is required for diverse ontogenic processes and as such identiﬁcation of the genes and
pathways affected by retinoic acid is critical to understanding these pleiotropic effects. The presomitic
mesoderm of the E8.5 mouse embryo is composed of undifferentiated cells that are depleted of retinoic
acid, yet are competent to respond to the retinoid signal. We have exploited these properties to use this
tissue to identify novel retinoic acid-responsive genes, including candidate target genes, by treating E8.5
embryos with retinoic acid and assessing changes in gene expression in the presomitic mesoderm by
microarray analysis. This exercise yielded a cohort of genes that were differentially expressed in
response to exogenous retinoic acid exposure. Among these were a number of previously characterized
retinoic acid targets, validating this approach. In addition, we recovered a number of novel candidate
target genes which were conﬁrmed as retinoic acid-responsive by independent analysis. Chromatin
immunoprecipitation assays revealed retinoic acid receptor occupancy of the promoters of certain of
these genes. We further conﬁrmed direct retinoic acid regulation of the F11r gene, a new RA target, using
tissue culture models. Our results reveal a signiﬁcant number of potential RA targets implicated in
embryonic development and offer a novel in vivo system for better understanding of retinoid-dependent
transcription.
& 2014 Elsevier Inc. All rights reserved.
Introduction
Retinoic acid (RA), the principal active metabolite of vitamin A,
plays fundamental roles in a number of developmental processes
ranging from axial patterning and cranio-facial development to
patterning of the central nervous system and organogenesis of
multiple systems (Ross et al., 2000; Blomhoff and Blomhoff., 2006;
Mark et al., 2006; Niederreither and Dolle, 2008). RA is also
required in the adult, where it plays roles in processes such as
learning, memory, immune function and reproduction (Blomhoff
and Blomhoff, 2006; Altucci et al., 2007).
The pleiotropic effects of RA are mediated by RARα, RARβ and
RARγ, members of the nuclear receptor superfamily which function
as ligand-dependent transcription factors. RARs form heterodimers
with the retinoid X receptors (RXRs), and mediate transcription by
binding as RXR–RAR heterodimers to cis acting RA response ele-
ments (RAREs) found in the promoter or enhancer regions of target
genes (Chambon, 1996; Balmer and Blomhoff, 2002, 2005; Blomhoff
and Blomhoff, 2006). Canonical RAREs consist of a direct repeat of
the sequence 50-PuG(G/T)(T/A)CA-30, typically separated by ﬁve
spacer nucleotides and referred to as a DR5 element (Perlmann
et al., 1993; Mangelsdorf and Evans, 1995; Bastien and Rochette-Egly,
2004). Notably, although such DR5 motifs have been described for a
number of RA targets, many retinoid-responsive genes harbor variant
RAREs (Balmer and Blomhoff, 2005), complicating assignment of
direct retinoid regulation by algorithm-based methods.
RA deﬁciency or excess or genetic disruption of RARs all result in
diverse developmental defects (Conlon, 1995; Marshall et al., 1996;
Mark et al., 2006, 2009). Together with reporter-based analysis of
biologically active retinoid signaling (Rossant et al., 1991), these
studies underscore a critical need for tight regulation of RA levels
and distribution in the developing embryo. This bio-availability is
controlled by the opposing actions of RA biosynthesis, including
generation of RA by retinaldehyde dehydrogenase (RALDH) family
members, and the degradation of RA by the cytochrome P450
family members CYP26A1, CYP26B1 and CYP26C1 (Maden et al.,
1998; Niederreither et al., 1999; Abu-Abed et al., 2003; Duester,
2008; Ross and Zolfaghari, 2011). Notably, the expression patterns
of CYP26A1, B1 and C1 are typically complementary to that of the
RALDHs (White et al., 1996; Fujii et al., 1997; Ray et al., 1997;
Hollemann et al., 1998; Duester, 2008; Uehara et al., 2009), and
disruption of retinoid metabolism through targeted deletion of
CYP26 or RALDH family members can evoke developmental defects
reﬂective of RA excess or deﬁciency, respectively.
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Central to understanding the biological roles of RA is the
identiﬁcation of retinoid target genes. Microarray and RNA-seq
technologies as well as Chromatin Immunoprecipitation (ChIP)-
seq methods, have revealed changes in gene expression evoked by
exogenous RA and genomic loci occupied by RARs, although such
work has largely been restricted to tissue culture models (Kim
et al., 2009; Delacroix et al., 2010; Mahony et al., 2011; Akanuma
et al., 2012; Moutier et al., 2012). While such models are useful
systems, they do not necessarily reﬂect the in vivo regulatory
hierarchies governed by RA, and as such our understanding of the
nature of RA target genes involved in development is incomplete.
The pre-somitic mesoderm (PSM) of the developing mouse
embryo represents a progenitor zone that is composed largely of
poorly differentiated tissue destined to contribute to the elongat-
ing axis. As development progresses, the anterior PSM condenses
at regular intervals to form somites, with tissue being replenished
by the addition of new cells provided by a proliferative precursor
population in the tail bud (Aulehla and Pourquie, 2010; Benazeraf
and Pourquie, 2013). The proliferation and subsequent differentia-
tion of the PSM is controlled by a network of factors including RA
which is generated in the trunk region just anterior to the
undifferentiated PSM (Ribes et al., 2009). The cells in the caudal
progenitor cell region, in contrast, express Cyp26A1 which is
believed to protect this population against precocious exposure
to RA (Fujii et al., 1997; Iulianella et al., 1999; Swindell et al., 1999).
This is underscored by the ﬁnding that loss of Cyp26A1 pheno-
copies many of the developmental defects that are elicited by
exogenous RA administered at E8.5 (Abu-Abed et al., 2001; Sakai
et al., 2001). Moreover, while Cyp26A1 does not require RA for
basal expression, as evidenced by its expression in RALDH2
mutants (Molotkova et al., 2005), it is directly regulated by
exogenous RA in an RARγ-dependent manner, suggesting a feed-
back mechanism to strictly regulate posterior RA levels (Lohnes
et al., 1994; Abu-Abed et al., 2003). In addition to Cyp26A1, RA also
impacts expression of a number of additional retinoid target genes
in the caudal embryo, such as Cdx1 (Houle et al., 2000, 2003). The
ﬁnding that Cdx1 expression, but not Cyp26A1, decreases signiﬁ-
cantly in the caudal region of Raldh2 / mutant embryos (Zhao
and Duester, 2009) further suggests at least two classes of RA
targets in the PSM; those that are expressed at a basal level
independent of retinoid signaling, but induced by RA, such as
Cyp26A1, and those that absolutely require RA for expression, such
as Cdx1.
The above observations indicate that the E8.5 caudal precursor
population is poised to respond to RA and therefore appears to be
a viable population to exploit for identiﬁcation of target genes
relevant to retinoid-dependent developmental programs. To this
end, we used microarray analysis to identify genes impacted by RA
in the PSM 3 h post-exposure. This analysis revealed a number of
genes previously shown to be RA-responsive, including known
direct target genes. In addition, we recovered a number of genes
that have not been previously identiﬁed as RA-responsive. We
conﬁrmed RA-regulation of several such genes, and used a newly
generated anti-RARγ antibody to demonstrate RARγ occupancy of
certain of these candidate targets. Our ﬁndings reveal a number of
potential new direct retinoid targets, and support the use of this
model system to identify RA targets relevant to development.
Material and methods
Mice
CD1 mice were mated overnight and noon of the day of the
vaginal plug was taken as embryonic day (E) 0.5. Pregnant females
were treated by oral gavage with either RA (100 mg/kg body
weight) or DMSO in corn oil at E8.5 and embryos harvested 3 h
post-treatment.
Microarray analysis
Total RNA was prepared from tissue caudal to the most recently
formed somite of stage-matched embryos (determined by somite
number) by Trizol extraction and RNA ampliﬁcation performed as
previously described (Hoffmann et al., 2002). Three independent
ampliﬁed RNA samples for each condition were hybridized to Affyme-
trix MO430_2.0 gene chips. Signal quantiﬁcation and normalization
was performed using MAS5, RMA and GC-RMA algorithms, and a t-test
performed to compare data sets and to provide a measure of variance.
False Discovery Rate Conﬁdence Interval (FDRCI) analysis was used to
establish signiﬁcance testing based on fold-change and variance.
Whole mount in situ hybridization
Whole mount in situ hybridization was performed as previously
described (Savory et al., 2009a). Probes for in situ hybridization were
generated from the following ESTs: Abtb2 (ATCC EST, IMAGE
6493840); Dgkz (ATCC EST, IMAGE 3668704); F11r (ATCC EST, IMAGE
3985305); Grsf1 (ATCC EST, IMAGE9834831); Irx3 (ATCC EST, IMAGE
30539191); Lhx1 (ATCC EST, IMAGE 30363447); Msi2h (ATCC EST,
IMAGE 40045350); Pim1 (ATCC EST, IMAGE 5694941); Ptprz (ATCC
EST, IMAGE 6403687); Ret (ATCC EST, IMAGE 6849696); Ror2 (ATCC
EST, IMAGE 4159363); Spsb4 (ATCC EST, IMAGE 6412566); Tshz1
(ATCC EST, IMAGE 5363241).
Fig. 1. False Discovery Rate Conﬁdence Interval (FDRCI) analysis. (A) For all data
sets a t-test was performed using three different algorithms to compare data sets
and to provide a measure of variance. FDRCI was done to obtain signiﬁcance testing
based on fold change and variance. A p-value of o1 was considered signiﬁcant for
the FDRCI analysis. (B) VENN diagram summarizing the results of the FDRCI
analysis with the three algorithms. Note the 109 common genes were determined
to be differentially regulated by RA with all three algorithms.
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Fig. 2. Hierarchical clustering by relative expression levels of gene expression proﬁles. Cluster heat map of the changes in the expression of the most robustly up regulated
(A) and the most severely down regulated (B) genes demonstrating segregation of RA treated and control samples.
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Generation of anti-RARγ antibody
Rabbit polyclonal anti-RARγ antibody was made by immuniza-
tion with a 136 bp fragment of the C-terminal F domain of RARγ
fused to GST which had been puriﬁed by standard means. Anti-
body speciﬁcity was assessed by Western blot using extracts
prepared from dorsal skin taken from E18.5 RARγ null, hetero-
zygous and WT mice.
Semi-quantitative RT-PCR
RNA extracted from the presomitic region of stage-matched
E8.5 embryos that had been treated in utero with either vehicle or
100 mg/kg RA was used to prepare cDNA by standard means. cDNA
was ampliﬁed by PCR using oligonucleotide primers as indicated,
with β-actin used as an internal control. PCR products were
resolved by agarose gel electrophoresis, quantiﬁed by scanning
densitometry and normalized relative to β-actin.
Chromatin immunoprecipitation (ChIP) assay
ChIP assays using chromatin prepared from E8.5 embryos were
performed as previously described (Savory et al., 2009a) using
anti-RARγ or anti-Cdx2 antibodies and pre-immune serum as a
negative control.
Electrophoretic mobility shift assay (EMSA)
The region of the F11r promoter region determined to be RA
responsive, by transient transfection analysis, was scanned for
RAR/RXR binding by electrophoretic mobility shift assay (EMSA).
EMSA was performed as previously described (Savory et al.,
2009a). The upper-stranded oligonucleotide used was 50-
AAGAATGTAAAACTTGCTGTTATCTTGACT. The RARE (DR5) oligo
50-GGGTAGGGTTCACCGAAAGTTCACTCGCA was used as a speciﬁc
competitor. Nuclear extracts from COS cells which had been either
mock transfected or transfected with expression vectors encoding
RARα and RXRγ were used as a source of protein.
Tissue culture and cell-based promoter analysis
Promoter sequences from candidate target genes were PCR
ampliﬁed from mouse genomic DNA, veriﬁed by sequencing and
subcloned into TK109 (Nordeen, 1988) to generate luciferase-based
reporter constructs. Transfection analyses were performed in P19
cells as previously described (Houle et al., 2000; Savory et al.,
2009b). Transfection mixes were comprised of 1 μg of the lucifer-
ase reporter construct (or empty vector control), 0.1 μg each of
RARγ and RXRα expression vectors and 0.2 μg RSV-Gal. β-
galactosidase activity was used to normalize for transfection
efﬁciency. All transfections were performed in triplicate and error
bars represent standard deviation from the mean.
Results
To identify RA-responsive genes, E8.5 embryos were treated with
either vehicle or RA in utero for 3 h and retinoid-responsive transcripts
identiﬁed by microarray analysis using representative RNA ampliﬁed
from three independent control or RA-treated caudal explants. Prin-
ciple Component Analysis using the Partek Genomics Suite 6.5 soft-
ware showed clear separation between the DMSO (vehicle) and RA
treated samples suggesting signiﬁcant differences in transcript dis-
tribution between the two populations (data not shown).
Signal quantiﬁcation and normalization was performed using
MAS5, RMA and GC RMA algorithms with a 1.5 fold change and a
false discovery rate conﬁdence interval p-value of o1 as the initial
boundaries for differential expression. As shown in Fig. 1A, a
signiﬁcant number of genes were RA-regulated, with the variation
in the number of responsive genes reﬂective of the stringency of
each algorithm. Results from the three algorithms identiﬁed a
common group of 109 differentially regulated genes (Fig. 1B) a
number of which were selected for further analysis.
RA responsive genes from the PSM include known target genes
Analysis of the RA-induced transcripts revealed several known
target genes, genes previously reported to be RA-responsive through
unknown mechanisms, and a number of genes that had not been
previously reported to be RA-dependent. Tables 1 and 2 list the most
robustly up regulated and repressed genes, respectively, while heat
maps (Fig. 2A and B) show clear segregation of the RA-treated and
control samples. Among the known RA targets were Cyp26a1 (Loudig
et al., 2000), Hoxa1 (Marshall et al., 1996), Cdx1 (Houle et al., 2000),
Arg1 (Chang et al., 2013) and Dhrs3 (Feng et al., 2010). RA-responsive
genes included Lhx1 (Hunter and Rhodes, 2005; Cartry et al., 2006),
Ptprz (Paschaki et al., 2013), Gcnf1 (Heinzer et al., 1998; Barreto et al.,
2003), Mrg1 (Oulad-Abdelghani et al., 1997) and Nrip1 (Kerley et al.,
2001). Genes previously reported to be repressed by RA, such as
Wnt5a (Kumar and Duester, 2010) and T (Iulianella et al., 1999), were
also recovered.
Functions of putative RA targets
We performed clustering analysis of the RA-induced genes to
gain potential insight into their biological functions. Responsive
genes encoded transcription factors, proteins involved in neuro-
genesis, anterior/posterior patterning, chromatin modiﬁcation and
AP pattern specification
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Fig. 3. Classiﬁcation of regulated genes. Differentially regulated genes (41.5 FC)
were categorized based on known or predicted functions. Functions are listed in
order of increasing (from bottom to top) statistical signiﬁcance [ log (p-values)] as
calculated by the Partek Genomic Suite software. (A) Gene Ontology enrichment
based on biological function. (B) Classiﬁcation based on pathways affected.
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metabolic processes (Fig. 3A). Many of these biological functions,
such as A/P patterning, cellular differentiation and transcriptional
regulation, are consistent with known roles for retinoid signaling
in development. In addition, retinoid signaling can impact many
other signaling pathways, and genes from a number of such
pathways were also affected by RA treatment (Fig. 3B).
Analysis of RA-responsive genes
Cohorts of genes that included known RA targets, RA respon-
sive genes and genes that have not been previously reported as
retinoid-responsive were selected for analysis by RT–PCR and/or
whole mount in situ hybridization. The overall validation rate by
RT–PCR was 96% (24/25; Fig. 4A), and many of the validated genes
have not been reported previously as RA responsive (e.g. Abtb2,
Spsb4). Whole mount in situ hybridization of several of these novel
candidate target genes revealed that their expression was induced
in the caudal embryo (e.g. F11r, Grsf1,Msi2h and Ret) while in other
cases induction was more widespread (e.g. Msi2h, Pim1, Tshz1 and
Spsb4) (Fig. 5). Of note, RA treatment induced expression of Lhx1 in
the caudal embryo, but also resulted in decreased Lhx1 expression
in the trunk of the embryo.
Generation and characterization of an RARγ speciﬁc antibody
We reasoned that a number of the genes recovered from the
microarray analysis are likely to be direct RA targets given their
rapid induction. To further assess this, we applied ChIP to assess
promoter occupancy by RAR. ChIP is highly dependent on the
quality of the antibody used for immunoprecipitation, and avail-
able RAR antibodies have not proven to be reliable for such
analysis in our hands. To circumvent this, we developed an anti-
RARγ antibody suitable for ChIP.
RARγ was chosen as it is expressed in the caudal embryo at
appropriate stages and is essential for regulating retinoid target genes,
such as Cyp26A1, in this domain (Ruberte et al., 1990; Abu-Abed et al.,
2003). In addition, the C-terminal 37 amino acid F domain chosen for
immunization is the least conserved region among the RARs (Bastien
and Rochette-Egly, 2004; Samarut and Rochette-Egly, 2012). Speciﬁcity
of the antibody was assessed by Western blot analysis using lysates
Table 3: Validation of Potential RA target genes
# genes in # genes tested % validatedset
HSIRCP-TRHSIRCPTRCF
>2 30 13 5 12 (92%) 5 (100%)
1.8 - 2 24 7 2 7 (100%) 2 (100%)
1.5 - 1.8 70 5 6 5 (100%) 6 (100%)
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Fig. 4. Semi-quantitative RT-PCR validation of putative RA target genes. (A) Compilation of validation data of differentially expressed genes. Note that there was an overall
validation rate of 96% (24/25 genes tested) by RT–PCR analysis. (B) Sample agarose gels of representative RT–PCR analysis showing differential expression of the indicated
genes in the caudal ends of E8.5 embryos treated for 3 h in utero with either DMSO (Control) or RA. Genes were selected based on the different FC from the microarray
analysis. (C) Relative mRNA expression calculated by scanning densitometry using β-actin as an internal control.
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prepared from the skin of wild-type, RARγþ / and RARγ/ mouse
embryos (Fig. 6). Skin was chosen as it expresses high levels of RARγ
(Krust et al., 1989; Zelent et al., 1989). A strong signal was observed at
the expected molecular weight in extracts from wild-type skin
whereas extracts from RARγ/ skin was devoid of signal. As
anticipated, lysates from RARγþ / skin displayed intermediate signal
intensity (Fig. 6A).
We further assessed the antibody by whole mount immuno-
histochemistry, which revealed staining in the caudal embryo, the
ﬁrst brachial arch, posterior neuroepithelium and lateral meso-
derm (Fig. 6B), consistent with the pattern of expression pre-
viously described for RARγ by whole mount in situ hybridization
(Abu-Abed et al., 2003).
To evaluate the antibody for ChIP analysis, immunoprecipitated
chromatin from E8.5 embryos was assessed for the recovery of the
Cyp26a1 and Cdx1 promoter regions, each of which harbors RAREs
(Houle et al., 2000; Loudig et al., 2000). In addition, the Cdx1
promoter contains a Cdx Response Element in close proximity to
the RARE (Beland et al., 2004), allowing a comparison of recovery
between anti-RARγ and anti-Cdx2 immunoprecipitation.
The regions of the Cyp26A1 and Cdx1 promoters harboring
RAREs were each speciﬁcally enriched by immunoprecipitation
with anti-RARγ (Fig. 6C). Furthermore, comparison of the RARγ
ChIP to that of Cdx2 ChiP on the Cdx1 promoter showed similar
recovery in both cases. These results validate the suitability of the
α-RARγ antibody for ChIP-based analysis.
ChIP analysis of putative RA target genes
The highly cryptic nature of RAREs confounded our search for
new RA targets by bioinformatics analysis. To circumvent this,
we designed the ChIP as ‘promoter walks’ to scan for RARγ
occupation in the region 10 kb upstream of the transcription
start sites of nine candidate target genes, using primer pairs at
2 kb intervals to amplify anti-RARγ immunoprecipitated chro-
matin. Although a band was occasionally observed in IgG control
precipitates (e.g. F11R 5 kb, Tshz1 9 kb) in each instance
enrichment with the RARγ antibody was signiﬁcantly greater.
RARγ occupancy was seen on at least one interval of each of the
promoters assessed (Fig. 7), with several genes exhibiting more
than one region of occupation, consistent with direct RA-
regulation of these genes.
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RA directly regulates F11r
Our ChIP data showed RARγ occupancy of the F11r promoter in
a region previously suggested to harbor a RARE (Fig. 8A) (Delacroix
et al., 2010). Reporter assays in P19 cells further revealed that this
region responded to RA (Fig. 8B). However, deletion analysis
suggested that the previously identiﬁed RARE in the F11r promoter
is not essential for RA-induced expression in vitro (Fig. 8B, M3).
Given the cryptic nature typical of RAREs we assessed RAR binding
of regions in this promoter by EMSA, and found RAR binding to
sequences distinct from the previously identiﬁed DR5 element
(Fig. 8C). Bioinformatics analysis did not identify RAREs in the
sequence bound by RAR/RXR in this assay, consistent with direct
regulation of F11r by RA through previously unrecognized, non-
canonical, motifs.
Discussion
The identiﬁcation of RA-regulated genes is essential to the
understanding of how retinoid signaling exerts its diverse effects.
We used a novel strategy that involved the isolation of embryonic
tissue poised to respond to RA, combined with microarray analysis
to identify potential RA target genes. Using a new and highly
speciﬁc RARγ antibody, we demonstrated RARγ occupancy on the
promoter regions of a number of these genes. In addition, we
showed that RAR bound directly to, and induced transcription
from, the proximal promoter of the F11r, a gene that responds to
RA in vivo. These results validate our approach and strongly
suggest that we have identiﬁed a cohort of novel target genes
involved in RA-dependent biological processes.
The PSM as an RA target tissue
The caudal PSM is a mesenchymal tissue with new cells generated
posteriorly from the tailbud of the developing embryo (Aulehla and
Pourquie, 2010; Benazeraf and Pourquie, 2013). These precursor
populations subsequently undergo differentiation mediated by a
number of different signaling pathways (Ribes et al., 2009). Embryo-
nic axis elongation, for example, is controlled by interplay between
the Wnt/β-catenin, Fgf and RA signaling pathways, with RA regulat-
ing several events related to segmentation of the mesoderm (Diez del
Corral and Storey, 2004; Olivera-Martinez and Storey, 2007; Ribes et
al., 2009; Cunningham et al., 2013). Wnt and Fgf ligands are
expressed in the caudal progenitor zone and are necessary for
maintaining axial progenitor cells (Dubrulle et al., 2001; Dubrulle
and Pourquie, 2002). RA signaling, beginning in late gastrulation,
promotes the down regulation of these Wnt and Fgf members in the
anterior PSM (Diez del Corral and Storey, 2004; Zhao and Duester,
2009). Consistent with this, the Wnt target genes Sall4 (Bohm et al.,
2006), Isl1 (Lin et al., 2007) and T (Yamaguchi et al., 1999; Arnold et
al., 2000) were all attenuated in our data set, in agreement with the
concept that RA promotes differentiation, in part, by restricting Wnt
and Fgf signaling.
Analysis of Raldh2 null mice previously revealed critical roles for
RA signaling in heart development (Niederreither et al., 2001).
Similar to it role in axis elongation, RA is thought to promote heart
development by repressing expression of certain genes. The heart
develops as a ventral tube along the A/P axis from a population of
cardiac progenitor cells called the ﬁrst heart ﬁeld (Vincent and
Buckingham, 2010). Additional cardiac precursor cells located in the
second heart ﬁeld are subsequently added to the growing heart. Isl1,
a second heart ﬁeld marker (Cai et al., 2003), is down regulated in
precursor cells as the cells are recruited into the growing heart tube
(Sirbu et al., 2008). Raldh2 / mutant mice have an enlarged heart
tube, and defects in looping concomitant with expansion of the
expression domains of second heart ﬁeld markers including Isl1
(Ryckebusch et al., 2008). These data are consistent with a role for
RA in establishing the boundaries of the second heart ﬁeld by
restriction gene expression. In agreement with this, Isl1 was down
regulated in our data set. Thus, these results further validate our
ﬁndings and support the use of the PSM as an in vivo model for
transcriptome analysis to identify novel RA-dependent pathways
and targets that have may evaded capture by other models.
Identiﬁcation of new RA target genes
The differentially expressed genes included a number of genes that
are either known RA target genes or genes reported to be RA-
responsive. Given this, and the low number of false positives from
the microarray, the novel differentially expressed genes that we
recovered are likely to include bona ﬁde targets. This is further
supported by whole mount in situ hybridization which conﬁrmed
that many of these genes are robustly induced 3 h post-RA treatment.
The list of RA-responsive genes encoded proteins implicated in a
wide variety of functions, consistent with the diverse effects of RA on
development. For example, genes involved in antero-posterior pat-
terning were well represented in our data set. This also holds true for
the list of novel candidate targets as potential targets such as Grsf1,
Ror2 and Prickle 1 have been suggested to play roles in AP patterning
and development (Lickert et al., 2005; Tao et al., 2009; Ho et al., 2012).
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Moreover, ChIP data suggests that many of these genes are likely to be
direct RA targets. The demonstration of direct regulation of the F11r
promoter by RA provides support for this proposal. F11r, also known as
junction adhesion molecule A (JAM-A), is a member of the junction
adhesion molecules family of proteins. As with other JAM members,
JAM-A is expressed at tight junctions of endothelial and epithelial cells
as well as on the surface of cells in the immune system. At these
intercellular junctions, JAMS associate with other components to
assemble and maintain tight junctions (Monteiro et al., 2013).
Given their expression patterns at epithelial and endothelial
junctions, as well as on circulating leucocytes, it is not surpris-
ing that JAMs have been identiﬁed as important players in the
control of vascular permeability as well as in the transmigration
of leukocytes across endothelial surfaces. JAM-A null mice, for
example, have increased intestinal permeability and reduced
resistance to trans-epithelial migration (Laukoetter et al., 2007;
Nava et al., 2011). Given these ﬁndings, it is possible that RA may
exert its well-known effects on epithelial function, in part,
through regulation of F11r expression (Jetten, 1991; Chytil,
1996; Osanai et al., 2007; Druilhe et al., 2008).
Our ﬁndings support the use of the E8.5 caudal embryo as a
tissue to analyze the network of genes regulated by RA in vivo.
We have identiﬁed potentially novel RA targets many of which
are consistent with known RA functions. We anticipate addi-
tional novel direct targets will be further identiﬁed utilizing
this approach.
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Fig. 7. RARγ binds to the promoter regions of potentially novel RA regulated genes. The 10 kb upstream regions of the indicated genes were scanned for RARγ occupancy by
ChIP assay. PCR analysis was designed a promoter walk with primer pairs spanning alternate 1 kb segments.
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Fig. 8. RARγ binds to and regulates transcription through sequences in the
proximal promoter region of the F11r gene. (A) Schematic of the control and
deletion reporter constructs of the F11r proximal promoter used for the transient
transfection assays. The red bars represent the position of a previously identiﬁed
DR-5 element (*) and the sequences used in the EMSA shown in panel C (**). (B) P19
cells transfected with the indicated construct were treated with 1 mM RA for 16 h
prior to assaying for luciferase activity. DR5 a reporter construct with a canonical
RARE was used as a positive control. All transfections were normalized relative to
β-galactosidase activity and performed in triplicate. Error bars indicate S.D. from
the mean. (C) RARγ binds to sequences in the proximal promoter region of F11r.
Binding of RARγ is speciﬁcally competed by a 100-fold excess of either unlabeled
self-oligonucleotide or a canonical DR5 RARE. Speciﬁcity was further demonstrated
by a super shift (ss) by anti-RARγ antibody. (For interpretation of the references to
color in this ﬁgure legend, the reader is referred to the web version of this article.)
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